STOCK TITAN

Trinity Biotech Plc - TRIB STOCK NEWS

Welcome to our dedicated page for Trinity Biotech Plc news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech Plc stock.

Trinity Biotech plc (NASDAQ: TRIB) is an international leader in the diagnostics industry, focusing on the development, manufacturing, and marketing of clinical diagnostic products for both clinical laboratories and point-of-care settings. Headquartered in Ireland, Trinity Biotech has been at the forefront of the industry since its formation in 1992, employing over 350 people and offering more than 400 products to customers in 80 countries.

Through a blend of organic growth and strategic acquisitions, Trinity Biotech has built a comprehensive portfolio of diagnostic products. These include test kits for the detection of infectious diseases, sexually transmitted diseases, autoimmune and hemoglobin disorders, and tools for diabetes monitoring and control. The company also supplies raw materials to the life sciences industry, expanding its influence and reach within the global market.

Trinity Biotech's product lineup features well-known brands such as Recombigen, Unigold, MarBlot, Mardx, and Immublot. The company's operations are geographically segmented into the Americas and the rest of the world, with a significant portion of its revenue derived from the Americas.

Recent developments have seen Trinity Biotech making significant strides in the diabetes management sector. The company recently acquired biosensor technology from Waveform Technologies Inc., marking its entry into the wearable biosensor market. This new venture aims to develop a range of biosensor devices, starting with a continuous glucose monitoring (CGM) product. To lead this initiative, Trinity Biotech appointed Avinash Kale as the Continuous Glucose Monitor Programme Director. Mr. Kale brings extensive experience in MedTech R&D and will play a pivotal role in advancing the company's CGM technology.

The company's commitment to innovation and excellence is evident in its ongoing projects and partnerships. Trinity Biotech continues to expand its product offerings and improve existing technologies to meet the needs of healthcare providers and patients worldwide. The company's dedication to quality and sustainability ensures that its diagnostic solutions remain at the cutting edge of the industry.

Trinity Biotech's financial performance for the fiscal year 2023 has been robust, with the company reporting significant growth and key business updates. The company's strategic focus on diabetes management solutions and human diagnostics positions it well for future success and shareholder value creation. For more details, visit Trinity Biotech's website.

Rhea-AI Summary

Trinity Biotech plc (Nasdaq: TRIB) announced the results of its Extraordinary General Meeting (EGM) held on January 25, 2022. Shareholders approved four resolutions necessary for the refinancing of approximately $99.9 million in exchangeable senior notes. Approval included a new term loan, increasing authorized share capital, and granting the board authority to issue shares without limit under Irish law. Notably, each resolution received at least 97% of the votes in favor, indicating strong shareholder support for these refinancing measures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.48%
Tags
none
-
Rhea-AI Summary

Trinity Biotech plc (TRIB) reported Q3 2021 revenues of $22.0 million, a decrease of 31.3% from $32.0 million in Q3 2020, largely due to a 40.3% drop in Clinical Laboratory revenues. Point-of-Care revenues rose by 99.2% to $4.1 million, driven by increased HIV testing in Africa. The company entered into an $81.25 million loan facility to refinance existing debt, with plans to retire $99.7 million in outstanding senior notes. Gross profit was $8.9 million, resulting in a margin of 40.4%. The company anticipates a positive future with innovative products and improved capital structure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.71%
Tags
buyback
-
Rhea-AI Summary

Trinity Biotech (Nasdaq: TRIB) reported Q2 2021 revenues of $25.8 million, up 61.3% from $16.0 million in Q2 2020. Point-of-Care revenue grew by 54.5% to $2.0 million, driven by increased HIV sales in Africa. Clinical Laboratory revenue surged 61.9% to $23.9 million, primarily due to COVID-19 related products. Gross profit was $11.0 million with a margin of 42.7%. Operating profit reached $6.3 million, markedly up from $0.5 million in the same period last year. The company anticipates regulatory approval for its new TrinScreen™ HIV test and aims to launch a COVID-19 rapid antigen test by Q2 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.32%
Tags
none
Rhea-AI Summary

Trinity Biotech plc (Nasdaq: TRIB) will report its financial results for Q2 FY 2021 on September 9, 2021. The company will hold a conference call at 11:00 am ET to discuss these results. The call will be accessible via US and international toll-free numbers, and it will also be webcasted live. A replay of the call will be available until September 16, 2021. Forward-looking statements in the release caution about potential risks, including challenges from COVID-19 and regulatory issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.6%
Tags
-
Rhea-AI Summary

Trinity Biotech (Nasdaq: TRIB) reported a business update for Q2 2021, highlighting advancements in their product lines. The company is advancing its TrinScreen™ HIV product through the WHO approval process, expected to increase market share in Africa. They are also developing a SARS-CoV-2 antigen test and pursuing an EUA for their antibody test, although the FDA has deprioritized this application, limiting its market potential. Additionally, Trinity is expanding lab services in New York, enhancing its diagnostic offerings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.83%
Tags
none
-
Rhea-AI Summary

Trinity Biotech (TRIB) reported a 20.9% revenue increase for Q1 2021, totaling $25.6 million, compared to $21.2 million in Q1 2020. Point-of-Care revenues fell 43.4% to $1.9 million due to COVID-19 related delays in HIV test orders. Conversely, Clinical Laboratory revenues grew 32.9% to $23.7 million, driven by strong sales of COVID-19 products, particularly PCR Viral Transport Media. Gross profit rose 17.6% to $10.9 million, but gross margin decreased to 42.6%. Overall, the company shows resilience amid pandemic challenges with expectations for revenue recovery in the Point-of-Care segment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.97%
Tags
none
Rhea-AI Summary

Trinity Biotech (Nasdaq: TRIB) announces its Q1 fiscal year 2021 financial results will be reported on May 25, 2021. A conference call is scheduled for the same day at 11:00 am ET, where details will be discussed. Interested parties can access the call via various toll-free numbers, including 1-844-861-5499 for US callers. A replay will be available until June 1, 2021 with access codes provided. The company specializes in diagnostic products for both point-of-care and clinical laboratory markets, focusing on infectious disease detection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
-
Rhea-AI Summary

Trinity Biotech has submitted its new HIV screening product, TrinScreen™ HIV, to the World Health Organisation (WHO) for approval. This product aims to enhance the company's existing HIV testing capabilities in Africa, building on its success with the Uni-Gold™ HIV test. The TrinScreen test detects HIV antibodies from a finger stick sample in under 12 minutes, boasting high assay sensitivity. A prior evaluation with 1,200 samples yielded excellent results. Approval from WHO is expected in months, during which the company will prepare for automated manufacturing in Ireland.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
none
-
Rhea-AI Summary

Trinity Biotech (TRIB) reported a 12.8% increase in fiscal year 2020 revenues to $102 million, up from $90.4 million in 2019. Point-of-care revenues decreased by 19.1% to $9.2 million, influenced by lower HIV sales and Covid-19 related logistical challenges. Conversely, clinical laboratory revenues surged 17.4% to $92.8 million, attributed to robust sales of Covid-19 products. The gross margin improved to 47.6%. Notably, the company achieved a profit after tax of $15.7 million, compared to a loss of $4.1 million in 2019, alongside a basic earnings per ADR of 75 cents.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.36%
Tags
Rhea-AI Summary

Trinity Biotech (Nasdaq: TRIB) announced that it will report its financial results for the fourth quarter and fiscal year 2020 on March 25, 2021. A conference call will be held on the same day at 11:00 am ET to discuss these results. Interested parties can join the call via US Toll Free or International Toll numbers, and a webcast will also be available. The company specializes in developing diagnostic products for point-of-care and clinical laboratory markets, serving customers globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.71%
Tags

FAQ

What is the current stock price of Trinity Biotech Plc (TRIB)?

The current stock price of Trinity Biotech Plc (TRIB) is $0.731 as of February 28, 2025.

What is the market cap of Trinity Biotech Plc (TRIB)?

The market cap of Trinity Biotech Plc (TRIB) is approximately 20.7M.

What does Trinity Biotech plc do?

Trinity Biotech plc develops, manufactures, and markets clinical diagnostic products for clinical laboratories and point-of-care settings. Their products are used to detect infectious diseases, autoimmune disorders, diabetes, and more.

Where is Trinity Biotech headquartered?

Trinity Biotech is headquartered in Ireland.

What recent developments have been made by Trinity Biotech?

Trinity Biotech recently acquired biosensor technology from Waveform Technologies Inc. and appointed Avinash Kale as the Continuous Glucose Monitor Programme Director to advance their CGM technology.

How many products does Trinity Biotech offer?

Trinity Biotech offers over 400 products.

In which markets does Trinity Biotech operate?

Trinity Biotech operates globally, with a significant portion of its revenue coming from the Americas. They market products in 80 countries.

What are some of Trinity Biotech's product brands?

Some of Trinity Biotech's product brands include Recombigen, Unigold, MarBlot, Mardx, and Immublot.

What is the significance of Trinity Biotech in the diagnostics industry?

Trinity Biotech is a leading player in the diagnostics industry, known for its comprehensive portfolio of diagnostic products and commitment to innovation and quality.

Who is the CEO of Trinity Biotech?

John Gillard is the CEO of Trinity Biotech.

What is Trinity Biotech's focus in recent years?

Trinity Biotech has been focusing on diabetes management solutions, including the development of continuous glucose monitoring (CGM) technology.

How can I learn more about Trinity Biotech's products and services?

You can learn more about Trinity Biotech's products and services by visiting their website at www.trinitybiotech.com.
Trinity Biotech Plc

Nasdaq:TRIB

TRIB Rankings

TRIB Stock Data

20.72M
14.03M
19.68%
23.96%
0.99%
Medical Devices
Healthcare
Link
Ireland
Bray